SPARK 15: The role of molecular mechanism of action in drug discovery strategies

| 05:00 PM - 07:00 PM
Fulginiti Pavilion for Bioethics and Humanites
13080 East 19th Avenue
Aurora, CO

Date : Feb 20
Place: Fulginiti Pavilion
Time 5-7pm

Speaker: David C. Swinney, PhD
Chief Executive Officer 

Learn more about Dr. Swinney in this interview.

Dr. Swinney is co-founder of iRND3 and has over 20 years broad experience with Syntex and Roche as a leader in pre-clinical drug discovery, primarily in the inflammation and virology disease areas. His previous position was Director of Virology Biochemical Pharmacology at Roche Palo Alto. Dr. Swinney has devoted the majority of his career to the identification of tractable drug targets, effective mechanisms of drug action, and promising leads and clinical candidates to address unmet medical needs. He has also developed an expertise in the understanding and application of binding kinetics of drug discovery. Dr. Swinney has a PhD in medicinal chemistry from the University of Washington and is author of over 100 publications in the fields of biochemistry and pharmacology.

Add event to:

CU Innovations

CU Anschutz

Anschutz Health Sciences Building

1890 N Revere Ct

Suite 6202

Mail Stop F411

Aurora, CO 80045


CMS Login